Verve Therapeutics Inc at Cowen Health Care Conference (Virtual) Transcript
Good morning, everyone. I'm Anvita Gupta from Cowen's biotech research team. It is my pleasure to introduce Verve Therapeutics for a formal presentation. Verve is making great strides at developing gene editing medicines to treat cardiovascular diseases with the lead program targeting heterozygous familial hypercholesterolemia. Here with us today is Verve's Co-founder and CEO, Sek Kathiresan. We have a little question and answer around at the end, if we have some time. (Operator Instructions)
With that, Sek, the floor is all yours.
Thank you very much, Anvita. Really a pleasure to be here. I appreciate the invitation from the Cowen team. So I'm going to share with you the story of Verve Therapeutics. We're looking to transform the treatment of cardiovascular disease from chronic management to single-course gene editing medicines. How are we going to do that? Here are 6 items that really highlight our differentiated
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
